Beckett, R.P., et al., “Recent Advances in Matrix Metalloproteinase Inhibitor Research”, Drug Disc. Today, 1, (1996), pp. 16-26. |
Brew, K., et al., “Tissue Inhibitors of Metalloproteinases: Evolution, Structure and Function”, Biochim. Biophys. Acta, 1477, (2000), pp. 267-283. |
Brown, S., et al., “Potent and Selective Mechanism-Based Inhibition of Gelatinases”, J. Am. Chem. Soc., 122, (2000), pp. 6799-6800. |
Bulychev, A., et al., “N-Sulfonyloxy-β-lactam Inhibitors for β-Lactamases”, Tetrahedron, 56, (2000), pp. 5719-5728. |
Dalberg, K.,et al., “Gelatinase A, Membrane Type 1 Matrix Metalloproteinase, and Extracellular Matrix Metalloproteinase Inducer mRNA Expression: Correlation with Invasive Growth of Breast Cancer”, World J. Surg., 24, (2000), pp. 334-340. |
Dumas, V., et al., “Expression of Basement Membrane Antigens and Matrix Metalloproteinases 2 and 9 in Cutaneous Basal and Squamous Cell Carcinomas”, A. Anticancer Res., 19, (1999), pp. 2929-2938. |
Forget, A-M, et al., “Physiological Roles of Matrix Metalloproteinases: Implications for Tumor Growth and Metastasis”, Can. J. Physiol. Pharmacol, 77, (1999), pp. 465-480. |
Freskos, J., “Discovery of a Novel Series of Selective MMP Inhibitors: Identification of the γ-Sulfone-Thiols”, Bioorg. & Med. Chem. Letters, 9, (1999), pp. 943-948. |
Fridman, R., et al., “Domain Structure of Human 72-kDa Gelatinase/Type IV Collagenase”, J. Biol. Chem., 267, (1992), pp. 15398-15405. |
Fridman, R., et al., “Expression of Human Recombinant 72 kDa Gelatinase and Tissue Inhibitor of Metallorproteinase-2 (TIMP-2): Characterization of Complex and Free Enzyme”, Biochem. J., 289, (1993), pp. 411-416. |
Greenwald, R.A., et al., “Inhibition of Matrix Metalloproteinase Therapeutic Applications”, Ann. N. Y. Acad. Sci., 878, (1999), pp. 412-419. |
Knight, C.G., “Fluorimetric Assays of Proteolytic Enzymes”, Methods Enzymol., 248, (1995), pp. 18-34. |
Massova, I., et al., “Matrix Metalloproteinases: Structures, Evolution, and Diversification”, FASEB J., 12, (1998), pp. 1075-1095. |
Massova, I., et al., “Structural Insights into the Catalytic Domains of Human Matrix Metalloprotease-2 and Human Matrix Metalloprotease-9: Implications for Substrate Specifities”, FASEB J., 12, (1998), pp. 17-30. |
Michaelides, M.R., et al., “Recent Advances In Matrix Metalloproteinase Inhibitors Research”, Curr. Pharm. Des. 5, (1999), pp. 787-819. |
Morgunova, E., et al., “Structure of Human Pro-Matrix Metalloproteinase-2: Activation Mechanism Revealed”, Science, 284, (1999), pp. 1667-1670. |
Nelson, A.R., et al., “Matrix Metalloproteinases: Biolegic Activity and Clinical Implications”, J. Clin. Oncol, 18, (2000), pp. 1135-1149. |
Olson, M., et al., “Characterization of the Monomeric and Dimeric Forms of Latent and Active Matrix Metalloproteinase-9”, J. Biol. Chem., 275, (2000), pp. 2661-2668. |
Pyke, C., et al., “Localization of Messenger RNA for Mr 72,000 and 92,000 Type IV Collagenases in Human Skin Cancers by in Situ Hybridization”, Cancer Res., 52, (1992), pp. 1336-1341. |
Salo, T., et al., “Purification and Characterization of a Murine Basement Membrane Collagen-degrading Enzyme Secreted by Metastatic Tumor Cells”, J. Biol. Chem., 258, pp. 3058-3063. |
Tamura, Y., “Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2): N-Sulfonylamino Acid Derivatives”, J. Med. Chem., 41, (1998), pp. 640-649. |
Westermarck, J., et al., “Regulation of Matrix Metalloproteinase Expression in Tumor Invasion”, FASEB J., 13, (1999), pp. 781-792. |